Endoscopy: Opening New Eyes, Series #8Hemospray™ in Gastrointestinal Bleeding
In this article we discuss the use of Hemospray™ (TC-325, Cook Medical Inc., Winston-Salem, NC, USA), a novel, highly adsorptive nanopowder made from a proprietary inorganic mineral blend. It has some distinct advantages over conventional endoscopic hemostatic modalities as it is easy to use and appears relatively safe and efficacious for various causes of both upper and lower gastrointestinal bleeding. It is currently licensed in Europe, Hong Kong and Canada for endoscopic hemostasis of non-variceal upper gastrointestinal bleeding and is undergoing Food and Drug Association evaluation in the United States.
Nutrition Issues in Gastroenterology, Series #129Trace Element Supplementation and Monitoring in the Adult Patient on Parenteral Nutrition
Often overlooked by medical providers, trace elements are essential nutrients for the long-term parenteral nutrition (PN) patient. They play a significant role in human metabolism and can lead to serious complications when deficient or in excess. Individual trace element regimens are determined by patient presentation, organ dysfunction, inflammation, and patient history. In this article we emphasize awareness of the complexity of trace elements and the understanding that careful monitoring of trace element status can improve patient success on PN.
Unusual Causes of Abdominal Pain, #4Unusual Causes of Abdominal Pain
A Case ReportAcute Hepatitis - Do Not Forget About Hepatitis E
Fellows' CornerAn Unusual Cause of Acute Pancreatitis
Inflammatory Bowel Diseases: Microbiota Versus the Barrier
With the rapid pace of research into the microbiome and the relative inaccessibility of this field to clinicians and non-microbiome researchers alike, references that clearly and concisely summarize the current literature are valuable. It is thus with interest that we reviewed the proceeding of the 188th Falk Symposium titled Inflammatory Bowel Diseases: Microbiota versus the Barrier.
Digestive Endoscopy: Terminology with Definitions and Classifications of Diagnosis and Therapy, 5th Edition
This 222-page book is available in both hard and softback versions along with an accompanying DVD. The book is written for the basic and post-graduate education of endoscopists.
The Gut Solution (For Parents with Children Who Have Recurrent Abdominal Pain and Irritable Bowel Syndrome)
To begin this review I must disclose that Dr, Lawson and I worked together for 12 years, and we remain in contact. However, I also must disclose that I have been present for much of the discussions that have lead to the development of this, so far, highly successful program for children with irritable bowel syndrome (IBS). The results of this work have been presented as oral presentations at Digestive Disease Week in 2013 and 2014.
The Little GI Book: An Easily Digestible Guide to Understanding Gastroenterology
This book is written in a wonderful conversational style that works well. The author, Douglas G. Adler MD, uses a bit of subtle humor that is not out of place even for a medical text. This particular style is foreshadowed by the book’s subtitle "An Easily Digestible Guide to Understanding Gastroenterology." Dr. Adler uses this style of writing as a means to emphasize important concepts and drive home potentially difficult-to- remember facts.
FIRST-OF-ITS-KIND MEDICAL DEVICE AVAILABLE TO PATIENTS WHO USE SUPPOSITORY MEDICATION
Sephure® Ensures Proper Placement of Suppositories and Improves Patient Quality of Life
NEW OLYMPUS EU-ME2 ULTRASOUND PROCESSOR DELIVERS VERSATILE, COST-EFFECTIVE RESOURCE FOR SHARING ACROSS SPECIALTIES
Ultrasound Imaging Platform Supports Better Detection and Characterization of Lesions in the Gastrointestinal Tract and Airways
ABBVIE SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR ITS INVESTIGATIONAL, ALL-ORAL, INTERFERON- FREE THERAPY FOR THE TREATMENT OF HEPATITIS C
- SUBMISSION BASED ON THE LARGEST PHASE III PROGRAM IN GENOTYPE 1 (GT1) HEPATITIS C PATIENTS CONDUCTED TO DATE 1
- ABBVIES INVESTIGATIONAL REGIMEN WAS DESIGNATED AS A BREAKTHROUGH THERAPY BY THE FDA
- ABBVIE PLANS TO SUBMIT APPLICATIONS FOR REGULATORY APPROVAL OF ITS REGIMEN IN THE EUROPEAN UNION IN EARLY MAY